Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma

ConclusionCombined detection of EGFR gene mutations as well as CA19-9 and CEA levels in peripheral blood can predict the efficacy of EGFR-TKI in the treatment of patients with lung adenocarcinoma.

http://link.springer.com/10.1007/s12094-018-02014-6

Source: Clinical and Translational Oncology - January 12, 2019 Category: Cancer & Oncology Source Type: research